Blueprint Medicines Corp. has synthesized EGFR (HER1; erbB1) inhibitors reported to be useful for the treatment of cancer, particularly non-small-cell lung cancer.
Shenzhen Maxinovel Pharmaceuticals Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase binding moiety covalently bonded to a Wee1-like protein kinase (Wee1)-targeting moiety through a linker.
Prelude Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (His1047Arg mutant) inhibitors reported to be useful for the treatment of cancer and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Denali Therapeutics Inc. has divulged NLRP3 inflammasome inhibitors reported to be useful for the treatment of Alzheimer's disease, atherosclerosis, asthma, nonalcoholic fatty liver disease (NAFLD), multiple sclerosis (MS), experimental autoimmune encephalitis, type 1 diabetes and rheumatoid arthritis, among others.
Nerviano Medical Sciences Srl has identified cyclin-dependent kinase 11A (CDK11A) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed HER2 (erbB2) and/or HER2 (erbB2) mutant inhibitors reported to be useful for the treatment of cancer.
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in a Shouyao Holdings (Beijing) Co. Ltd. patent to be useful for the treatment of cancer.
A team at Berrybio (Shanghai) Ltd. has prepared proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to focal adhesion kinase (FAK)-targeting moiety through a linker.
Beigene Ltd. has disclosed new Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) inhibitors reported to be useful for the treatment of cancer, viral infections, age-related issues, neurological, immunological and inflammatory disorders.
RSS